G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms
- PMID: 28007579
- DOI: 10.1016/j.bbagen.2016.12.015
G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms
Abstract
Background: AS1411 is a 26-mer G-rich DNA oligonucleotide that forms a variety of G-quadruplex structures. It was identified based on its cancer-selective antiproliferative activity and subsequently determined to be an aptamer to nucleolin, a multifunctional protein that preferentially binds quadruplex nucleic acids and which is present at high levels on the surface of cancer cells. AS1411 has exceptionally efficient cellular internalization compared to non-quadruplex DNA sequences.
Scope of review: Recent developments related to AS1411 will be examined, with a focus on its use for targeted delivery of therapeutic and imaging agents.
Major conclusions: Numerous research groups have used AS1411 as a targeting agent to deliver nanoparticles, oligonucleotides, and small molecules into cancer cells. Studies in animal models have demonstrated that AS1411-linked materials can accumulate selectively in tumors following systemic administration. The mechanism underlying the cancer-targeting ability of AS1411 is not completely understood, but recent studies suggest a model that involves: (1) initial uptake by macropinocytosis, a form of endocytosis prevalent in cancer cells; (2) stimulation of macropinocytosis by a nucleolin-dependent mechanism resulting in further uptake; and (3) disruption of nucleolin-mediated trafficking and efflux leading to cargoes becoming trapped inside cancer cells.
Significance: Human trials have indicated that AS1411 is safe and can induce durable remissions in a few patients, but new strategies are needed to maximize its clinical impact. A better understanding of the mechanisms by which AS1411 targets and kills cancer cells may hasten the development of promising technologies using AS1411-linked nanoparticles or conjugates for cancer-targeted therapy and imaging. This article is part of a Special Issue entitled "G-quadruplex" Guest Editor: Dr. Concetta Giancola and Dr. Daniela Montesarchio.
Keywords: AS1411; Aptamer; Cancer; Contrast agent; Drug delivery; Imaging; Nanoparticles; Nucleolin; Quadruplex; Radiosensitizer.
Copyright © 2016. Published by Elsevier B.V.
Similar articles
-
The cellular protein nucleolin preferentially binds long-looped G-quadruplex nucleic acids.Biochim Biophys Acta Gen Subj. 2017 May;1861(5 Pt B):1371-1381. doi: 10.1016/j.bbagen.2016.11.036. Epub 2016 Nov 30. Biochim Biophys Acta Gen Subj. 2017. PMID: 27913192 Free PMC article.
-
Tandem application of ligand-based virtual screening and G4-OAS assay to identify novel G-quadruplex-targeting chemotypes.Biochim Biophys Acta Gen Subj. 2017 May;1861(5 Pt B):1341-1352. doi: 10.1016/j.bbagen.2017.01.024. Epub 2017 Jan 24. Biochim Biophys Acta Gen Subj. 2017. PMID: 28130159
-
Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.Sci Rep. 2019 May 28;9(1):7945. doi: 10.1038/s41598-019-44388-9. Sci Rep. 2019. PMID: 31138870 Free PMC article.
-
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.Exp Mol Pathol. 2009 Jun;86(3):151-64. doi: 10.1016/j.yexmp.2009.01.004. Epub 2009 Jan 20. Exp Mol Pathol. 2009. PMID: 19454272 Free PMC article. Review.
-
EMICORON: A multi-targeting G4 ligand with a promising preclinical profile.Biochim Biophys Acta Gen Subj. 2017 May;1861(5 Pt B):1362-1370. doi: 10.1016/j.bbagen.2016.11.010. Epub 2016 Nov 9. Biochim Biophys Acta Gen Subj. 2017. PMID: 27838395 Review.
Cited by
-
Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells.Cancers (Basel). 2022 Sep 27;14(19):4698. doi: 10.3390/cancers14194698. Cancers (Basel). 2022. PMID: 36230620 Free PMC article.
-
Self-Assembled DNA Nanostructure as a Carrier for Targeted siRNA Delivery in Glioma Cells.Int J Nanomedicine. 2021 Mar 3;16:1805-1817. doi: 10.2147/IJN.S295598. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33692623 Free PMC article.
-
The Impact of PEGylation on Cellular Uptake and In Vivo Biodistribution of Gold Nanoparticle MRI Contrast Agents.Bioengineering (Basel). 2022 Dec 4;9(12):766. doi: 10.3390/bioengineering9120766. Bioengineering (Basel). 2022. PMID: 36550972 Free PMC article.
-
Improvement of the activity of the anti-HIV-1 integrase aptamer T30175 by introducing a modified thymidine into the loops.Sci Rep. 2018 May 10;8(1):7447. doi: 10.1038/s41598-018-25720-1. Sci Rep. 2018. PMID: 29749406 Free PMC article.
-
Anti-nucleolin aptamer AS1411: an advancing therapeutic.Front Mol Biosci. 2023 Sep 21;10:1217769. doi: 10.3389/fmolb.2023.1217769. eCollection 2023. Front Mol Biosci. 2023. PMID: 37808518 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous